Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
Holding JNJ?
Track your performance easily
JNJ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$143.13 - $168.85
Previous Close$143.85
Volume10.34M
Average Volume (3M)6.99M
Market Cap
$346.34B
Enterprise Value$361.79B
Total Cash (Recent Filing)$20.30B
Total Debt (Recent Filing)$35.75B
Price to Earnings (P/E)24.2
Beta0.24
Next Earnings
Jan 22, 2025EPS Estimate
$2.02Last Dividend Ex-Date
Nov 26, 2024Dividend Yield3.35%
Share Statistics
EPS (TTM)6.05
Shares Outstanding2,407,622,972
10 Day Avg. Volume8,976,261
30 Day Avg. Volume6,991,115
Standard Deviation0.05
R-Squared0.28
Alpha-0.00071
Financial Highlights & Ratios
Price to Book (P/B)4.94
Price to Sales (P/S)4.03
Price to Cash Flow (P/CF)11.00
P/FCF Ratio12.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.53
Enterprise Value/Gross Profit6.17
Enterprise Value/Ebitda14.74
Forecast
1Y Price Target
$175.69Price Target Upside20.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJNJ reported 3Q EPS of $2.42, 10% above consensus.
Product Approval And EfficacyIcotrokinra demonstrated superior efficacy over other oral treatments, including Sotyktu, TAK-279, and Otezla.
Strategic Growth And AcquisitionsJNJ is willing to make bigger acquisitions, indicating the strength of its balance sheet and the potential for impactful investments.
Bears Say
EarningsJNJ reduced its 2024 adjusted operational EPS guidance to $9.86-$9.96 from $10.00-$10.10 to account for the impact of V-Wave.
Product SalesBiosimilars of J&J’s bestselling product Stelara (12.8% sales FY23) are expected to be launched in the US and its sales are expected to get slashed.
Sales GrowthJNJ lowered its full-year adjusted operational sales growth target for MedTech to 'closer to 5%' from 6% previously due to softness in the Asia-Pacific region, particularly in China.
---
Ownership Overview
0.04% Insiders
18.48% Mutual Funds
14.63% Other Institutional Investors
45.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $143.13 and its highest was $168.85 in the past 12 months.
What is Johnson & Johnson’s market cap?
Currently, no data Available
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jan 22, 2025 which is in 35 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Oct 15, 2024. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.207 by $0.213.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.24 which represents an annual dividend yield of 3.35%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is $2.02.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,623,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.42 in its last earnings report, beating expectations of $2.207. Following the earnings report the stock price went up 1.547%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 1B.
---
Johnson & Johnson Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$175.69 (20.00% Upside)
$175.69 (20.00% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 189.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $147.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.35%
12-Months-Change
Fundamentals
Return on Equity
20.89%
Trailing 12-Months
Asset Growth
7.36%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
JNJ Company Deck
---
JNJ Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
Johnson & Johnson reported robust sales growth and pipeline advancements in Q3 2024, particularly in Innovative Medicine and MedTech segments. However, earnings were impacted by legal settlement costs and challenges in the Asia Pacific region. Despite these challenges, the company remains confident in its growth trajectory.Read More>---
JNJ Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
$175.69
▲(20.00% Upside)
Technical Analysis
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
22/23 ratings generated profit
1 Year Average Return
+9.23%
reiterated a buy rating 7 months ago
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 95.65% of your transactions generating a profit, with an average return of +9.23% per trade.
---